EMV Shares EMVision Medical Devices Ltd
ASX · ASXLast in our picks 2026-10-25 — not in the current list; analysis below is from that screen
Portable brain-imaging technology targets underserved emergency care with substantial commercialization upside.
Signal breakdown
- ▸Product development milestones and recent positive sector momentum.
- ▾Below 50-day MA (-13.72%)
- ▸Volume 1.77× average — accumulation
- ▾Near 52-week low (1% of range)
Is EMV a buy right now?
Trend: EMV is trading below the 50-day average (-8.04%), RSI 38 — neutral momentum, with a 3-month return of -3.13%.
Valuation & quality: EMVision Medical Devices Ltd trades on forward P/E -9.4, price-to-book 9.09; fundamentals show net margin -99.5%, return on equity -66.4%, revenue growth 187.5% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$3.15 (+103.9% vs the last close; range A$3.15 – A$3.15), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Portable brain-imaging technology targets underserved emergency care with substantial commercialization upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -10.80% | +13.40% | -3.40% | -12.20% | +6.00% | +6.90% | -7.00% | -3.10% |
Fundamentals
Analyst price target
Technical signals
About EMVision Medical Devices Ltd
EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia.
Sector: Healthcare · Industry: Medical Devices · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.